期刊
CLINICAL IMMUNOLOGY
卷 135, 期 3, 页码 466-475出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2010.01.014
关键词
Treg; CCR6; TIL; Breast cancer; Prognosis
类别
资金
- China National Natural Science Foundation [30890140, 30671952]
- National High Technology Research and Development Program of China [2007CB512401]
- Program for Outstanding Medical Academic Leader [LJ06011]
CCR6(+) subset of CD4(+) regulatory T cells, a newly characterized subset of Tregs, has been reported to contribute to local immune inhibition. However, whether CCR6(+) Tregs are present in tumor environment and their relation to the prognosis of tumor remain to be elucidated. In this study, we found that CCR6(+) CD4(+) CD25(high) Tregs, expressing high levels of CD45RO, are dominantly enriched in tumor mass from patients with breast cancer. Furthermore, the frequency of CCR6(+) Tregs, but not CCR6 Tregs in tumor infiltrating lymphocytes (TILs), significantly increased in patients during tumor progression, which reversely correlated with decreased frequency of the IFN-gamma(+)CD8(+)T cells in TILs. Most importantly, the frequency of CCR6(+) Tregs, but not CCR6(-) Tregs, reversely correlated to the survival of patients with breast cancer. This study suggested that a new subset of tumor-resident Tregs, CCR6(+) Tregs, may be dominantly responsible for the immunosuppression in tumor immunity and a potential predictor of the poor prognosis of breast cancer. (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据